natgillin/translations-raw huggingface dataset:
The Hirobriz Breezhaler inhaler provided with each new prescription should be used. 
Kasutada tuleb iga uue retseptiga ette nähtud Hirobriz Breezhaler inhalaatorit.
The Hirobriz Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD. 
Hirobriz Breezhaler'i III faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske KOK.
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Hirobriz Breezhaler inhaler. 
Soovitatavaks annuseks on ühe 150-mikrogrammise kapsli sisu inhalatsioon üks kord päevas Hirobriz Breezhaler inhalaatorist.
Immediate hypersensitivity reactions have been reported after administration of Hirobriz Breezhaler. 
On teatatud kohestest ülitundlikkusreaktsioonidest pärast Hirobriz Breezhaler'i manustamist.
Other medicines and Hirobriz Breezhaler 
Muud ravimid ja Hirobriz Breezhaler
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Hirobriz Breezhaler at the recommended doses than on placebo. 
Kliinilistes uuringutes esines Hirobriz Breezhaler'i soovitatavate annuste kasutamisel veresuhkru taseme kliiniliselt väljendunud muutusi üldiselt sagedamini (1...2% võrra) kui platseebo puhul.
Paediatric population There is no relevant use of Hirobriz Breezhaler in the paediatric population (under 18 years). 
Puudub Hirobriz Breezhaler'i asjakohane kasutus lastel (vanuses alla 18 aasta).
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Hirobriz Breezhaler at recommended therapeutic doses (see section 5.1). 
Hirobriz Breezhaler'i kliinilistes uuringutes ei ole soovitatavate terapeutiliste annuste kasutamisel täheldatud kliiniliselt olulisi toimeid QTc-intervalli pikenemisele (vt lõik 5.1).
What Hirobriz Breezhaler contains - Each Hirobriz Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate. 
Mida Hirobriz Breezhaler sisaldab - Iga Hirobriz Breezhaler 150-mikrogrammine kapsel sisaldab 150 mikrogrammi indakaterooli indakateroolmaleaadina.
• Only use the Hirobriz Breezhaler inhaler contained in this pack. 
• Kasutage ainult selles pakendis sisalduvat Hirobriz Breezhaler inhalaatorit.
Always keep the Hirobriz Breezhaler inhaler and capsules in a dry place. 
Hoidke Hirobriz Breezhaler inhalaatorit ja kapsleid alati kuivas kohas.
Hirobriz Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function. 
Hirobriz Breezhaler'i manustamine üks kord päevas annustes 150 ja 300 mikrogrammi viis kopsufunktsiooni kliiniliselt olulise paranemiseni.
Hirobriz Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar. 
Hirobriz Breezhaler 300-mikrogrammistele kapslitele on trükitud sinises kirjas toote kood „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
What you need to know before you use Hirobriz Breezhaler 
Mida on vaja teada enne Hirobriz Breezhaler'i kasutamist
Hirobriz Breezhaler capsules must not be swallowed. 
Hirobriz Breezhaler kapsleid ei tohi alla neelata.
Hirobriz Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar. 
Hirobriz Breezhaler 150-mikrogrammistele kapslitele on trükitud mustas kirjas toote kood „IDL 150“ musta joone kohale ja firma logo ( ) musta joone alla.
Only use the capsules with the inhaler provided in this pack (Hirobriz Breezhaler inhaler). 
Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Hirobriz Breezhaler inhalaator).
An increase in the daily dose of Hirobriz Breezhaler beyond the maximum dose of 300 microgram is not appropriate. 
Hirobriz Breezhaler'i ööpäevast annust ei tohi suurendada üle maksimaalse annuse, milleks on 300 mikrogrammi.
Hirobriz Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators. 
Hirobriz Breezhaler sisaldab toimeainena indakaterooli, mis kuulub bronhodilataatoriteks ehk bronhilõõgastiteks nimetatud ravimite rühma.
There are no data available for use of Hirobriz Breezhaler in patients with severe hepatic impairment. 
Puuduvad andmed Hirobriz Breezhaler'i kasutamise kohta raske maksakahjustusega patsientidel.
Hirobriz Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy. 
Hirobriz Breezhaler ei ole näidustatud ägedate bronhospasmi episoodide raviks, st hooravimina.
- Each Hirobriz Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate. 
- Iga Hirobriz Breezhaler 300-mikrogrammine kapsel sisaldab 300 mikrogrammi indakaterooli indakateroolmaleaadina.
When you start a new pack, use the new Hirobriz Breezhaler inhaler that is supplied in the pack. 
Kui alustate uue pakendi kasutamist, kasutage pakendis olevat uut Hirobriz Breezhaler inhalaatorit.
Only use the Hirobriz Breezhaler inhaler contained in this pack. 
Kasutage ainult selles pakendis sisalduvat Hirobriz Breezhaler inhalaatorit.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in a capsule. 
Hirobriz Breezhaler inhalaator võimaldab kapslis sisalduvat ravimit sisse hingata.
Carton containing 30 capsules and one Hirobriz Breezhaler inhaler. 
Karbis on 30 kapslit ja üks Hirobriz Breezhaler inhalaator.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in an Hirobriz Breezhaler capsule. 
Hirobriz Breezhaler inhalaator võimaldab sisse hingata Hirobriz Breezhaler kapslis sisalduvat ravimit.
Carton containing 10 capsules and one Hirobriz Breezhaler inhaler. 
Karbis on 10 kapslit ja üks Hirobriz Breezhaler inhalaator.
You should not use Hirobriz Breezhaler unless your doctor tells you so. 
Hirobriz Breezhaler'it tohib kasutada ainult juhul, kui arst seda soovitab.
What Hirobriz Breezhaler is and what it is used for 
Mis ravim on Hirobriz Breezhaler ja milleks seda kasutatakse
Talk to your doctor or pharmacist before using Hirobriz Breezhaler if you have asthma (in this case you should not use Hirobriz Breezhaler). 
Enne Hirobriz Breezhaler'i kasutamist pidage nõu oma arsti või apteekriga: kui teil on astma (sellisel juhul ei tohi Hirobriz Breezhaler'it kasutada); kui teil on probleeme südamega; kui teil on epilepsia; kui teil on probleeme kilpnäärmega (türeotoksikoos); kui teil on suhkurtõbi.
Hirobriz Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD). 
Hirobriz Breezhaler'it kasutatakse hingamise kergemaks muutmiseks kroonilisest obstruktiivsest kopsuhaigusest (KOK) tingitud hingamisraskustega täiskasvanutel.
Hirobriz Breezhaler is a single-dose inhalation device. 
Hirobriz Breezhaler on inhalatsiooniseade ühekordse annuse manustamiseks.
Driving and using machines It is unlikely that Hirobriz Breezhaler will affect your ability to drive and use machines. 
On ebatõenäoline, et Hirobriz Breezhaler võiks mõjutada autojuhtimise ja masinatega töötamise võimet.
Always use the new Hirobriz Breezhaler inhaler that comes with your new pack. 
Kasutage alati uut Hirobriz Breezhaler inhalaatorit, mis on uues pakendis.
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). 
Hirobriz Breezhaler on näidustatud bronhe lõõgastavaks säilitusraviks hingamisteede obstruktsiooni korral kroonilise obstruktiivse kopsuhaigusega (KOK) täiskasvanud patsientidel.
Show the pack of Hirobriz Breezhaler. 
Näidake Hirobriz Breezhaler'i pakendit.
Never wash the Hirobriz Breezhaler inhaler with water. 
Ärge kunagi peske Hirobriz Breezhaler inhalaatorit veega.
Never place a Hirobriz Breezhaler capsule directly into the mouthpiece of the Hirobriz Breezhaler inhaler. 
Ärge kunagi pange Hirobriz Breezhaler kapslit otse Hirobriz Breezhaler inhalaatori huulikusse.
Breezhaler capsules with any other inhaler, and do not use Hirobriz Breezhaler inhaler to take any other capsule medicine. 
Hirobriz Breezhaler kapsleid üheski teises inhalaatoris, samuti ärge kasutage Hirobriz
Reports of hypersensitivity have been received from post-approval marketing experience in association with the use of Hirobriz Breezhaler. 
Turuletulekujärgselt on teatatud Hirobriz Breezhaler'i kasutamisega seotud ülitundlikkusest.
If you forget to inhale a dose, inhale just one dose at the usual time the next day. 
Kui te unustate Hirobriz Breezhaler'it kasutada Kui te unustate annuse sisse hingamata, hingake järgmisel päeval tavalisel ajal sisse vaid üks annus.
How much Hirobriz Breezhaler to use 
Kui palju Hirobriz Breezhaler'it kasutada
What Hirobriz Breezhaler is used for 
Milleks Hirobriz Breezhaler'it kasutatakse
Never take the Hirobriz Breezhaler inhaler apart. 
Ärge kunagi võtke Hirobriz Breezhaler inhalaatorit osadeks lahti.
Do not swallow Hirobriz Breezhaler capsules. 
Ärge neelake Hirobriz Breezhaler kapsleid.
Do not store the capsules in the Hirobriz Breezhaler inhaler. 
Ärge hoidke kapsleid Hirobriz Breezhaler inhalaatoris.
How to use Hirobriz Breezhaler 
Kuidas Hirobriz Breezhaler'it kasutada
Hirobriz Breezhaler inhaler 
HIROBRIZ BREEZHALER INHALAATORI KASUTUSJUHEND
For inhalation use only. 
Ainult inhalatsiooniks.
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indakaterool (indacaterolum)
How to store Hirobriz Breezhaler 
Kuidas Hirobriz Breezhaler'it säilitada
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
In particular, please tell your doctor if you are using: medicines for breathing problems that are similar to Hirobriz Breezhaler (i.e. medicines such as salmeterol and formoterol). 
Hirobriz Breezhaler'iga sarnased ravimid (ravimid nagu salmeterool ja formoterool) hingamisprobleemide leevendamiseks.
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules 
Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites
• When you start a new pack, only use the new Hirobriz Breezhaler inhaler that is supplied in the pack. 
• Kui alustate ravimi kasutamist uuest pakendist, kasutage uut pakendis olevat Hirobriz
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules 
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites
During treatment with Hirobriz Breezhaler, Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. 
Kui teil tekib vahetult pärast ravimi kasutamist rindkere pingsus, köha, vilisev hingamine või hingeldus, lõpetage otsekohe ravimi kasutamine ja teavitage sellest oma arsti.
What Hirobriz Breezhaler is 
Mis ravim on Hirobriz Breezhaler
Inhaler base 
Breezhaler inhalaator
700 micrograms 
700 mikrogrammi Klaaskehasisene implantaat aplikaatoris.
Intravitreal implant in applicator Intravitreal use pouch (foil) 1 pouch with applicator system 
1 kotike aplikaatorsüsteemiga
The company has presented data from both laboratory and field studies on the effectiveness of the vaccine against the two bacteria. 
Tootja esitas nii labori- kui ka väliuuringute andmed, et tõendada vaktsiini efektiivsust nimetatud kahe bakteri vastu.
Sows that have been vaccinated according to this scheme before need a single revaccination two to four weeks before the expected farrowing date. 
Selle skeemi kohaselt juba vaktsineeritud emised vajavad ühekordset revaktsineerimist 2-4 nädalat enne eeldatavat poegimiskuupäeva.
E. Coli and C. perfringens vaccine 
E. Coli ja C. perfringens vaktsiin
Reduced activity and lack of appetite on the day of vaccination commonly occurs. 
Sageli esinevad vaktsineerimispäeval aktiivsuse vähenemine ja isu puudumine.
This summary was last updated on 14 June 2012. 
Kokkuvõtte viimane uuendus: 14/06/2012.
A sometimes painful and hard swelling up to 10 cm in diameter may be observed at the injection site for up to 25 days. 
Mõnikord võib täheldada süstekohal kuni 25 päeva valulikku ning kõva turset läbimõõduga kuni 10 cm.
The withdrawal period for Porcilis ColiClos is zero days for pig meat. 
Porcilis ColiClosi keeluaeg on sealiha puhul null päeva.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or the label shown to the physician. 
Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
The European Commission granted a marketing authorisation valid throughout the European Union, for Porcilis ColiClos on 14 June 2012. 
Euroopa Komisjon andis vaktsiini Porcilis ColiClos müügiloa, mis kehtib kogu Euroopa Liidus, 14/06/2012.
The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption. 
Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha või piima toiduks tarvitada.
The first injection is given to sows or gilts, six or eight weeks before the expected farrowing (giving birth) date and a second injection is given four weeks later. 
Emiseid ja nooremiseid süstitakse esimest korda 6 või 8 nädalat enne eeldatavat poegimist ja teine kord 4 nädalat hiljem.
It may also reduce the use of antimicrobials in pig production units. 
See võib aidata vähendada ka mikroobivastaste ravimite kasutamist seafarmides.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Porcilis ColiClos exceed the risks and recommended that Porcilis ColiClos be given a marketing authorisation. 
Veterinaarravimite komitee järeldas, et Porcilis ColiClosi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiinile müügiloa.
To demonstrate protection against E.coli infection, studies were also presented with Porcilis Porcoli Diluvac Forte, a vaccine authorised within the EU with the same E. coli components as Porcilis ColiClos. 
Et tõendada vaktsiini efektiivsust E.coli infektsiooni vastu, esitati ka Porcilis Porcoli Diluvac Forte uuringute andmed - see vaktsiin, millel on juba Euroopa Liidus müügiluba, sisaldab samu E. coli osi mis Porcilis ColiClos.
Porcilis ColiClos contains parts of the bacteria E. coli and C. perfringens that have been inactivated so that they cannot cause disease. 
Porcilis ColiClos sisaldab bakterite E. coli ja C. perfringens osi, mis on inaktiveeritud ega saa seetõttu haigust tekitada.
Porcilis ColiClos is given by injection into a muscle in the neck area behind the ear. 
Porcilis ColiClosi süstitakse kaelalihasesse kõrva taha.
Porcilis ColiClos contains an adjuvant to enhance the immune response. 
Porcilis ColiClos sisaldab parema immuunvastuse saamiseks ka adjuvanti.
It contains parts of the Escherichia coli (E. coli) bacterium called fimbrial adhesins F4ab, F4ac, F5 and F6 and LT toxoid (weakened toxin), as well as toxoid of the Clostridium perfringens (C. perfringens) bacterium type C. 
Porcilis ColiClos sisaldab bakteri Escherichia coli (E. coli) osi fimbriaalseid adhesiine F4ab, F4ac, F5 ja F6 ning LT toksoidi (nõrgestatud toksiini), samuti bakteri Clostridium perfringens (C. perfringens) C-tüübi toksoidi.
Porcilis ColiClos is a vaccine. 
Porcilis ColiClos on vaktsiin.
When Porcilis ColiClos is given to sows or gilts, the pig's immune system recognises the inactivated bacteria as ‘foreign' and makes antibodies against them. 
Kui emistele või nooremistele manustatakse vaktsiini, peab nende immuunsüsteem inaktiveeritud baktereid võõraks ja tekitab nende vastu antikehi.
Other information about Porcilis ColiClos: 
Muu teave Porcilis ColiClosi kohta
What is the risk associated with Porcilis ColiClos? 
Mis riskid Porcilis ColiClosiga kaasnevad?
An increase in body temperature of up to 2°C may be observed on the day of vaccination. 
Vaktsineerimisjärgsel päeval on täheldatud kehatemperatuuri tõusu (kuni 2Ԩ).
These antibodies are transferred from the mother to the piglets through the colostrum (first milk), and they help the piglets to fight E. coli or C. perfringens infection if they become exposed after birth. 
Need antikehad kanduvad ternespiimaga emiselt põrsastele ja aitavad põrsastel bakteritega E. coli ja C. perfringens võidelda, kui nad pärast sündi nendega kokku puutuvad.
Porcilis ColiClos is given to sows (female pigs that have already given birth to piglets) or gilts (female pigs that have not yet given birth to piglets) to provide their offspring with protection against infections caused by E. coli strains that express the components F4ab, F4ac, F5 or F6, and by C. perfringens type C. The vaccine is used to reduce death and clinical signs of infections caused by these bacteria during the first days of life. 
Vaktsiini Porcilis ColiClos antakse emistele (poeginud emastele sigadele) või nooremistele (poegimata emastele sigadele), et immuniseerida nende põrsaid infektsioonide vastu, mida põhjustavad adhesiine F4ab, F4ac, F5 või F6 ekspresseerivad bakteri E. coli tüved ja bakteri C. perfringens C-tüüp.
Porcilis ColiClos has been shown to reduce death and the clinical signs of E. coli or C. perfringens infections such as neonatal piglet diarrhoea and necrotic enterotoxaemia (a severe infection of the intestines). 
On tõendatud, et Porcilis ColiClos vähendab bakterite E. coli ja C. perfringens põhjustatud infektsioonidest, nagu vastsündinud põrsaste kõhulahtisus ja nekrootiline enterotokseemia (äge soolenakkus) tingitud surmajuhtumeid ja kliinilisi nähte.
Porcilis ColiClos is a vaccine that is available as a suspension for injection. 
Porcilis ColiClos on vaktsiin, mida turustatakse süstesuspensioonina.
What is Porcilis ColiClos? 
Mis on Porcilis ColiClos?
How does Porcilis ColiClos work? 
Kuidas Porcilis ColiClos toimib?
Why has Porcilis ColiClos been approved? 
Miks Porcilis ColiClos heaks kiideti?
How has Porcilis ColiClos been studied? 
Kuidas Porcilis ColiClosi uuriti?
What is Porcilis ColiClos used for? 
Milleks Porcilis ColiClosi kasutatakse?
What benefit has Porcilis ColiClos shown during the studies? 
Milles seisnes uuringute põhjal Porcilis ColiClosi kasulikkus?
Route of Administration 
Revimi nimetus
Treatment may be restarted once the patient's condition has stabilised. 
Ravi tohib taasalustada, kui patsiendi seisund on stabiliseerunud.
The review of SGLT2 inhibitors was initiated at the request of European Commission in June 2015, under Article 20 of Regulation (EC) No 726/2004. 
SGLT2 inhibiitorite läbivaatamine algatati juunis 2015 Euroopa Komisjoni nõudel määruse (EÜ) nr 726/2004 artikli 20 kohaselt.
An atypical presentation of diabetic ketoacidosis can delay diagnosis and treatment. 
Diabeetilise ketoatsidoosi atüüpiline avaldumine võib diagnoosimist ja ravi edasi lükata.
You may need emergency treatment and your diabetes medicine may need to be changed. 
Te võite vajada erakorralist ravi ja teile võidakse määrata muu diabeediravim.
The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 25/04/2016 (Invokana, Jardiance) and 28/04/2016 (Forxiga, XigDuo, Synjardy, Vokanamet). 
Inimravimite komitee arvamus edastati Euroopa Komisjonile, kes tegi 25/04/2016 (Invokana, Jardiance) ja 28/04/2016 (Forxiga, XigDuo, Synjardy, Vokanamet) õiguslikult siduva lõpliku otsuse, mida kohaldatakse kõigis Euroopa Liidu liikmesriikides.
On 25 February 2016, the European Medicines Agency (EMA) confirmed recommendations1 to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines). 
Euroopa Ravimiamet (EMA) kinnitas 25. veebruaril 2016 soovitused1, kuidas minimeerida diabeetilise ketoatsidoosi riski patsientidel, kes kasutavad SGLT2 inhibiitoreid (2. tüüpi diabeedi ravimiklass).
• SGLT2 inhibitors in the EU are available under the following trade names: Ebymect, Edistride, Forxiga, Invokana, Jardiance, Synjardy, Vokanamet and Xigduo. 
• Euroopa Liidus turustatakse SGLT2 inhibiitoreid järgmiste kaubanduslike nimetuste all: Ebymect, Edistride, Forxiga, Invokana, Jardiance, Synjardy, Vokanamet ja Xigduo.
• Inform patients of the signs and symptoms of diabetic ketoacidosis and advise them to seek medical advice immediately if they develop such signs and symptoms. 
• Teatage patsiente diabeetilise ketoatsidoosi nähud ja sümptomid ning öelge, et nad peavad otsekohe pöörduma arsti poole, kui neil esineb loetletud nähte ja sümptomeid.
The following SGLT2 inhibitors are authorised in the EU: Ebymect (dapagliflozin/metformin), Edistride (dapagliflozin), Forxiga (dapagliflozin), Invokana (canagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin / metformin), Vokanamet (canagliflozin / metformin) and Xigduo (dapagliflozin / metformin). 
Euroopa Liidus on müügiluba järgmistel SGLT2 inhibiitoritel: Ebymect (dapagliflosiin/metformiin), Edistride (dapagliflosiin), Forxiga (dapagliflosiin), Invokana (kanagliflosiin), Jardiance (empagliflosiin), Synjardy (empagliflosiin/metformiin), Vokanamet (kanagliflosiin/metformiin) ja Xigduo (dapagliflosiin/metformiin).
• Always consider the possibility of diabetic ketoacidosis in patients taking SGLT2 inhibitors who have non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. 
• Arvestage alati diabeetilise ketoatsidoosi võimalust SGLT2 inhibiitoreid kasutavatel patsientidel, kellel esinevad mittespetsiifilised sümptomid, näiteks iiveldus, oksendamine, isutus, kõhuvalu, liigne janu, hingamisraskused, segasus, ebatavaline väsimus või unisus.
• Stop treatment with SGLT2 inhibitors immediately if diabetic ketoacidosis is suspected or confirmed, and do not re-start treatment unless another clear precipitating factor for the condition is identified and resolved. 
• Lõpetage ravi SGLT2 inhibiitoritega otsekohe, kui kahtlustate diabeetilist ketoatsidoosi või see on kinnitatud, ja ärge taasalustage ravi, enne kui seisundi muu võimalik tegur on tuvastatud ja kõrvaldatud.
• Healthcare professionals are reminded that SGLT2 inhibitors are only authorised for treating type 2 diabetes. 
• Tervishoiutöötajatele meenutatakse, et SGLT2 inhibiitorid on heaks kiidetud kasutamiseks üksnes 2. tüüpi diabeedi raviks.
• If you have any of the symptoms above while taking an SGLT2 inhibitor, contact a doctor or the nearest hospital straightaway even if your sugar level is not particularly high. 
• Kui võtate SGLT2 inhibiitoreid ja teil esineb mõni nimetatud sümptomitest, pöörduge otsekohe arsti poole või lähimasse haiglasse, isegi kui vere glükoosisisaldus ei ole väga suur.
They block a protein in the kidneys called SGLT2, which absorbs glucose back from the urine into the bloodstream as the blood is filtered in the kidneys. 
Need blokeerivad neerudes valgu SGLT2, mis absorbeerib glükoosi uriinist tagasi vereringesse, kui veri filtreerub neerudes.
• Diabetic ketoacidosis is a serious complication of diabetes. 
• Diabeetiline ketoatsidoos on raske diabeeditüsistus.
Following a review of the cases, EMA recommended updating the product information of SGLT2 inhibitors to list diabetic ketoacidosis as a rare adverse reaction (affecting up to 1 in 1,000 patients). 
Pärast juhtude läbivaatamist soovitas EMA uuendada SGLT2 inhibiitorite ravimiteavet, et lisada harvaesineva kõrvaltoimena diabeetiline ketoatsidoos (esineb kuni 1 patsiendil 1000st).